Navigation Links
Decision Resources' Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
Date:10/26/2010

BURLINGTON, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that because Phase III trials of Pfizer's tanezumab for the treatment of osteoarthritis pain were halted over U.S. Food & Drug Administration safety concerns, Decision Resources' Pharmaview 2016 global sales forecast for tanezumab has been reduced by $1.2 billion to $200 million. The decision to end the trial was made after a subset of patients in the trial required joint replacement surgery due to worsened conditions.

The discontinuation of the trial is a setback for the drug and a concern for the entire drug class, as tanezumab was the most clinically advanced agent of a family of anti-nerve growth factor (NGF) monoclonal antibodies (MAbs). Anti-NGF MAbs have garnered considerable attention from large pharmaceutical companies for the novel mechanism of action; Sanofi-Aventis (SAR164877), Johnson & Johnson (AMG-403) and Abbott (PG-110) are each in an early-stage program.

"With Lipitor, Celebrex and Viagra all facing patent expiries over the next several years, Pfizer greatly needs new agents to fill the revenue gap," said Pharmaview Analyst Michael Latwis, M.B.A. "Unfortunately, given that approval for osteoarthritis pain—the largest potential market for tanezumab—is highly unlikely, our Pharmaview model does not expect sales to reach anywhere near blockbuster status."

New Pharmaview Platform ReleasedDecision Resources has released a new delivery platform for its Pharmaview product. Pharmaview provides continually updated analysis on more than 2,100 drugs from more than 250 companies, covering 150 product classes and 14 therapy areas—complete with more than 1,200 product-level forecasts.

The new platform includes not only expanded coverage of the biopharmaceutical industry, but enhanced functionality including improved search capabilities an
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
2. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
3. FDAs Just Approved Monthly Drug Treatment, Vivitrol Could Be Game Changer, Says Countrys Largest Drug Treatment Recovery President, CRCs Jerry Rhodes; Provides Addicts One Decision A Month Instead of 30
4. Decision Resources Launches Analogue Tool To Help Pharmaceutical Companies Quickly Assess Market Opportunity
5. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
6. Wise Sky Highlights Their Disappointment at Emergents Decision Not to Enter the China Market
7. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
8. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
9. Medco CEO to Present at the Sanford C. Bernstein & Co., LLC 26th Annual Strategic Decisions Conference 2010
10. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
11. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/24/2013)... Western University of Health Sciences’ College of ... for the next seven years from the American Veterinary ... is a magnificent achievement, and one we expected as ... said College of Veterinary Medicine Dean Phillip Nelson, DVM, ... faculty, staff, preceptors, and students that participated in generating ...
(Date:5/24/2013)... -- New research suggests a link between sleep ... Every additional hour someone with insomnia sleeps ... the likelihood of moderate or high risk of ... Pennsylvania. "We were surprised by the ... suicide risk," study author, Linden Oliver, clinical research ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Started in 1982, ... held in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is ... starting with supermodel Millie Lewis and her daughter, Carey Lewis ... agents, managers, casting directors, and music professionals including the New ... and XP Media. They are kings of Hollywood and Christian ...
(Date:5/24/2013)... York (PRWEB) May 24, 2013 The ... involving Intuitive Surgical Inc.’s da Vinci Surgical System ... court records, a Washington State Court jury ruled in ... in training a surgeon who performed a da Vinci ... The patient’s family had alleged in their lawsuit ...
(Date:5/24/2013)... 24, 2013 Mike Stoler believes that ... successful business people in New York. That’s why ... weekly on CUNY TV. And that’s why he ... Allergy Associates, LLP (ENTA)—the largest single specialty practice in ... throat, allergy and audiology specialists and sub-specialists service communities ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4
... FDA,s Advisory, ALBUQUERQUE, N.M., Jan. 18 Yesterday ... that over-the-counter (OTC),cough and cold products should not be ... of age because serious and potentially life-threatening,side effects can ... release,there are a wide variety of rare, serious, and ...
... --Texas Childrens Hospital has been named the national ... of the German-manufactured pediatric heart pump called Berlin ... D. Fraser, Jr., MD, chief of pediatric and ... Michael E. DeBakey Department of Surgery at Baylor ...
... First and only medication approved to reduce both ... 18 Daiichi Sankyo, Inc.,announced today that the ... Welchol(TM) (colesevelam HCl) to improve glycemic control,(measured as ... mellitus in,combination with metformin, sulfonylureas, or insulin, either ...
... ANGELES, Jan. 18 Hyland,s, Inc. wants to,remind ... and flu,season, Hyland,s homeopathic medicines remain a safe ... common cough and cold,symptoms., Today, the Food ... of over-the-counter (OTC) cough and cold,products in children ...
... and other parts of the University of California, San ... and climate change - were awarded supercomputing time by ... its 2008 Innovative and Novel Computational Impact on Theory ... Office of Science awarded a record 265 million hours ...
... for women who do not have osteoporosis , , FRIDAY, ... benefits and downplay the risks of prescribing bone-strengthening drugs ... not have osteoporosis, a new report claims. , Drugs ... risk of fractures of women with osteoporosis, according to ...
Cached Medicine News:Health News:Solutions for Parents Who Need Cold Remedies for Their Children 2Health News:National study will look at German-made heart pump for children needing heart transplants 2Health News:National study will look at German-made heart pump for children needing heart transplants 3Health News:Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 2Health News:Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 3Health News:Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 4Health News:Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 5Health News:Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 6Health News:Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 7Health News:Hyland's Cough and Cold Medicines Remain a Safe and Effective Option for Toddlers and Young Children 2Health News:DOE awards supercomputing time to UCSD, SDSC researchers 2Health News:DOE awards supercomputing time to UCSD, SDSC researchers 3Health News:Bone-Strengthening Drugs May Be Overprescribed 2Health News:Bone-Strengthening Drugs May Be Overprescribed 3
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... The AMS 700 Series is an advanced three-part ... the abdomen, a pump placed in the scrotum ... corpora cavernosa. It closely simulates the look and ... for innovative penile implant technology, the AMS 700 ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
Medicine Products: